Ankoor Shah, MD
Internal Medicine · Durham, NCNPI 1306024161
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,780 of the $4,718 with a category attached, or 80.1%. Boehringer Ingelheim accounts for 61.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $2,900 and has fallen 69.7% since, to $880 in 2025. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 4 payments — averaging $1179.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- E.r. Squibb & Sons, L.L.C.$938
- Tanabe Pharma America, Inc.$880
Across 109 payments — averaging $6695.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$384K
- Amgen$336K
- Boehringer Ingelheim Pharma GmbH & Co.kg$10K
What the payments were for
- Consulting fees$3,78080%
- Speaking & faculty fees$93820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $2,900 |
| E.r. Squibb & Sons, L.L.C. | 1 | $938 |
| Tanabe Pharma America, Inc. | 2 | $880 |
How this compares
$4,718 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ambrisentan | 22 | $115,295 |
| ActemraTocilizumab | 14 | $58,867 |
| Mycophenolate Mofetil | 96 | $15,100 |
| Mycophenolic AcidMycophenolate Sodium | 26 | $12,485 |
| Tadalafil | 16 | $5,770 |
| Hydroxychloroquine Sulfate | 101 | $3,743 |
| Azathioprine | 19 | $2,007 |
| Esomeprazole Magnesium | 19 | $1,709 |
| MethotrexateMethotrexate Sodium | 44 | $972 |
| Sildenafil Citrate | 24 | $907 |
| Omeprazole | 42 | $907 |
| Leflunomide | 15 | $857 |
| Gabapentin | 70 | $775 |
| Prednisone | 66 | $365 |
| Pantoprazole Sodium | 27 | $337 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Durham
- Nirmish ShahDurham$862K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Patricia LugarDurham$197K
- Rebecca RichDurham$160K
- Adam DevoreDurham$112K
- Kevin ThomasDurham$101K
- Julius WilderDurham$97K
- Richard RiedelDurham$95K
- Jennifer RymerDurham$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.